Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Yin, Jie ^a   Chen, Guowei ^a   Liu, Yucun ^a   Liu, Si ^a   Wang, Pengyuan ^a   Wan, Yuanlian ^a   Wang, Xin ^a   Zhu, Jing ^a   Gao, Hongqiao ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN; SMALL INTERFERING RNA; MESSENGER RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; COCARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; STOMACH CANCER; TRANSIENT TRANSFECTION; CELL ADHESION; CELL CYCLE; CELL MOTION; DRUG ANTAGONISM; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 77952823856     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-59     Document Type: Article

References (34)

1. Cancer Incidence, Mortality and Prevalence Worldwide, version 2.0. International Agency for Research on Cancer (2004) Globocan 2002, IARC CancerBase no. 5 Lyon, France: IARC Press, Ferlay J, Bray F, Pisani P, Parkin DM
2. Global cancer statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 2 74 108 10.3322/canjclin.55.2.74 15761078
3. Pattern of changing incidence of gastric cancer and its time trend in Shanghai. ZYBP Wu Chun-xiao, 2008 13 24 29
4. SPARC, a matricellular glycoprotein with important biological functions. Q Yan EH Sage, J Histochem Cytochem 1999 47 12 1495 1505 10567433
5. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. AD Bradshaw EH Sage, J Clin Invest 2001 107 9 1049 1054 10.1172/JCI12939 11342565
6. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. OL Podhajcer LG Benedetti MR Girotti F Prada E Salvatierra AS Llera, Cancer Metastasis Rev 2008 27 4 691 705 10.1007/s10555-008-9146-7 18542844
7. Distribution of SPARC in normal and neoplastic human tissue. PL Porter EH Sage TF Lane SE Funk AM Gown, J Histochem Cytochem 1995 43 8 791 800 7622842
8. Differential expression of osteonectin/SPARC during human prostate cancer progression. R Thomas LD True JA Bassuk PH Lange RL Vessella, Clin Cancer Res 2000 6 3 1140 1149 10741745
9. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. F Ledda AI Bravo S Adris L Bover J Mordoh OL Podhajcer, J Invest Dermatol 1997 108 2 210 214 10.1111/1523-1747.ep12334263 9008236
10. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. SA Rempel WA Golembieski S Ge N Lemke K Elisevich T Mikkelsen JA Gutierrez, J Neuropathol Exp Neurol 1998 57 12 1112 1121 10.1097/00005072-199812000-00002 9862633
11. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. GK Yiu WY Chan SW Ng PS Chan KK Cheung RS Berkowitz SC Mok, Am J Pathol 2001 159 2 609 622 11485919
12. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. EN Yang HJ Kang KH Koh H Rhee NK Kim HG Kim, Int J Cancer 2007 121 3 567 575 10.1002/ijc.22706 17397030
13. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. PA Puolakkainen RA Brekken S Muneer EH Sage, Mol Cancer Res 2004 2 4 215 224 15140943
14. Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. G Chen X Tian Z Liu S Zhou B Schmidt D Henne-Bruns M Bachem M Kornmann, Br J Cancer 2010 102 1 188 195 10.1038/sj.bjc.6605440 19920824
15. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. JF DiMartino NJ Lacayo M Varadi L Li C Saraiya Y Ravindranath R Yu BI Sikic SC Raimondi GV Dahl, Leukemia 2006 20 3 426 432 10.1038/sj.leu. 2404102 16424866
16. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. CS Wang KH Lin SL Chen YF Chan S Hsueh, Brit J Cancer 2004 91 11 1924 1930 10.1038/sj.bjc.6602213 15558074
17. Osteonectin/SPARC/BM-40 in human decidua and carcinoma, tissues characterized by de novo formation of basement membrane. UM Wewer R Albrechtsen LW Fisher MF Young JD Termine, Am J Pathol 1988 132 2 345 355 3400777
18. Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. HY Maeng SB Song DK Choi KE Kim HY Jeong Y Sakaki C Furihata, Cancer Lett 2002 184 1 117 121 10.1016/S0304-3835(02)00191-X 12104055
19. SPARC is associated with gastric cancer progression and poor survival of patients. ZS Zhao YY Wang YQ Chu ZY Ye HQ Tao, Clin Cancer Res 2010 16 1 260 268 10.1158/1078-0432.CCR-09-1247 20028745
20. Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread. K Franke S Carl-McGrath FW Rohl U Lendeckel MP Ebert M Tanzer M Pross C Rocken, Transl Oncol 2009 2 4 310 320 19956393
21. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. MF Ledda S Adris AI Bravo C Kairiyama L Bover Y Chernajovsky J Mordoh OL Podhajcer, Nat Med 1997 3 2 171 176 10.1038/nm0297-171 9018235
22. Appearance of osteonectin-expressing fibroblastic cells in early rat stomach carcinogenesis and stomach tumors induced with N-methyl-N '-nitro-N-nitrosoguanidine. HY Maeng DK Choi M Takeuchi M Yamamoto M Tominaga T Tsukamoto M Tatematsu T Ito Y Sakaki C Furihata, Japanese Journal of Cancer Research 2002 93 9 960 967 12359048
23. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. M Inoue S Senju S Hirata Y Ikuta Y Hayashida A Irie M Harao K Imai Y Tomita T Tsunoda Y Furukawa T Ito Y Nakamura H Baba Y Nishimura, Int J Cancer 2010
24. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. H Porte E Chastre S Prevot B Nordlinger S Empereur P Basset P Chambon C Gespach, Int J Cancer 1995 64 1 70 75 10.1002/ijc.2910640114 7665251
25. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. PM Tremble TF Lane EH Sage Z Werb, J Cell Biol 1993 121 6 1433 1444 10.1083/jcb.121.6.1433 8509459
26. SPARC: a potential diagnostic marker of invasive meningiomas. SA Rempel S Ge JA Gutierrez, Clin Cancer Res 1999 5 2 237 241 10037170
27. Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. J Schittenhelm M Mittelbronn F Roser M Tatagiba C Mawrin A Bornemann, Neuropathol Appl Neurobiol 2006 32 5 525 531 10.1111/j.1365-2990.2006.00761.x 16972886
28. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Q Shi S Bao L Song Q Wu DD Bigner AB Hjelmeland JN Rich, Oncogene 2007 26 28 4084 4094 10.1038/sj.onc.1210181 17213807
29. Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. K Horie M Tsuchihara T Nakatsura, Cancer Sci 2009 20100207
30. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. Q Shi S Bao JA Maxwell ED Reese HS Friedman DD Bigner XF Wang JN Rich, J Biol Chem 2004 279 50 52200 52209 10.1074/jbc.M409630200 15469933
31. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. N Said I Najwer K Motamed, Am J Pathol 2007 170 3 1054 1063 10.2353/ajpath.2007.060903 17322388
32. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. IT Tai M Dai DA Owen LB Chen, J Clin Invest 2005 115 6 1492 1502 10.1172/JCI23002 15902309
33. SPARC in cancer biology: its role in cancer progression and potential for therapy. IT Tai MJ Tang, Drug Resist Updat 2008 11 6 231 246 10.1016/j.drup.2008.08.005 18849185
34. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. ML Iruela-Arispe TF Lane D Redmond M Reilly RP Bolender TJ Kavanagh EH Sage, Mol Biol Cell 1995 6 3 327 343 7612967